Drug delivery and formulation - Page 1Stay up to date with the latest Drug delivery and formulation updates from the global world pharmaceuticals industry
Latest Drug delivery and formulation Update
The Falsified Medicines Directive (FMD) is a new EU initiative which comes...
> read more
UK Pharma Warns that skills shortage and Brexit will hit R&D
The Association of the British Pharmaceutical Industry (ABPI) has warned that the UK is in danger of losing its world-leading research and development status
Including prices on TV ads only works when the price is listed alone
The Trump administration's proposal to require pharmaceutical companies to list drug prices in television ads is unlikely to have a large impact on the way consumers think about...
New code of practice for pharma freebies
On 1 January 2019, the new code of practice of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) came into effect
Neopac unveils SteriDrop tube for preservative-free eyedrops
Switzerland-based Hoffmann Neopac has unveiled SteriDrop tube, a tube and dispenser solution which is claimed to offer combination of product protection and user-friendliness.
FDA approves drug to treat binge eating disorder
A new drug that treats moderate-to severe binge eating disorder (BED) in adults has been approved by FDA, The Obesity Society (TOS) has reported. The prescription drug,...
Nexavar given green light to treat thyroid cancer
Nexavar, the drug developed by Bayer and Amgen unit Onyx Pharmaceuticals to treat advanced kidney and liver cancers, has been approved for the treatment of the most common form of...
GSK diabetes drug Eperzan approved in Europe
The European Commission has granted marketing authorisation for GlaxoSmithKline's (GSK) once-weekly diabetes treatment, Eperzan (albiglutide).
Pfizer announces positive top-line results of landmark CAPiTA evaluating efficacy of Prevenar 13
Pfizer Inc has announced that the 'Community-Acquired Pneumonia Immunisation Trial in Adults' (CAPiTA) − the landmark study of approximately 85,000 subjects evaluating the efficacy...
Novartis drug Lucentis approved by Japanese regulatory bodies
Lucentis® (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: the treatment of patients with diabetic macular edema (DME), a leading cause of...
GSK announces start of Phase lll study for mepolizumab in patients with EGPA
GlaxoSmithKline (GSK) has announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, in patients with...